This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced or metastatic triple-negative breast cancer. Phase I uses a modified 3+3 dose-escalation design to determine safety, tolerability, maximum tolerated dose, and recommended Phase II dose. Phase II uses a Simon two-stage expansion design at the recommended Phase II dose to evaluate preliminary antitumor activity, including objective response rate per Response Evaluation Criteria in Solid Tumors.
Clinically defined histologically or cytologically confirmed triple-negative breast cancer (TNBC)
Locally advanced unresectable or metastatic disease
Must have completed prior anticancer therapy discontinued for a least 28 days
Disease progression after prior systemic therapy for advanced/metastatic TNBC
HER2-positive or hormone receptor-positive breast cancer
Active leptomeningeal disease
Uncontrolled, symptomatic CNS metastases
Concurrent participation in another interventional clinical trial
Sequential
Zn-Telomir
DrugZn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reduces tumor DNA methylation, and kills cancer cells in an iron-dependent manner - targeting epigenetic and metal homeostasis drivers of cancer cell survival.
Phase I: Incidence of Serious Adverse Events (SAEs) and incidence and severity of Treatment-Emergent AEs (TEAEs)
Phase II: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
Phase I: Maximum Plasma concentration (Cmax)
Phase I: Half-life (T1/2)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
